BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

CIN: L24233MP1985PLC002709

Registered Office: 11/12, Sector E Sanwer Road, Indore-452015 (M.P.) Tel. 0731-2723016; Email id- bcplcompliance@gmail.com; Website- www.biofilgroup.net; Fax: 0731-2723017

Date: 11th February, 2025

To, To. The Secretary (DCS/Compliance), The Secretary (Listing/Compliance), Corporate Relationship Department, Stock **Exchange National** of India **BSE Limited (DCS/Compliance)** Limited. Phiroze Jeejeebhoy Towers, Dalal Street, Exchange Plaza, C-1, Block G, Bandra Kurla Mumbai-400001 Complex, Mumbai - 400051

Subject: Integrated Filing (Financial) for the quarter and nine-months ended 31st December, 2024.

Reference: Biofil Chemicals and Pharmaceuticals Limited (BSE Scrip Code: 524396; NSE Symbol: BIOFILCHEM; ISIN: INE829A01014)

Dear Sir/Madam,

In accordance with amendments to the SEBI (Listing Obligations and Disclosure Requirements) (Third Amendment) Regulations, 2024 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31st December, 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated 2nd January, 2025, we are enclosing herewith the Integrated Filing (Financial) for the quarter and nine-months ended 31st December, 2024 for your reference and records.

The above information will also be available on the website of the Company at www.biofilgroup.net.

You are requested to take on record the above said information for your reference and records.

Thanking you,

Yours Faithfully

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

RAMESH SHAH CHAIRMAN & MANAGING DIRECTOR DIN: 00028819

Enclosed: As above

ANNEXURE A- FINANCIAL RESULTS FOR THE QUARTER AND NINE-MONTHS ENDED 31ST DECEMBER, 2024. (attach Full results with limited review and segment if any as filed with exchange)

ANNEXURE B STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC: NOT APPLICABLE

ANNEXURE C: FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES –

S. No	Particulars	In INR Crore	
1.	Loans/ revolving facilities like cash credit from banks/	0.00	
	financial institutions		
A.	Total amount outstanding as on date	0.00	
B.	Of the total amount outstanding, amount of default as on	0.00	
	date		
2.	Unlisted debt securities i.e. NCDs and NCRPS	0.00	
A.	Total amount outstanding as on date	0.00	
B.	Of the total amount outstanding, amount of default as on	0.00	
	date		
3.	Total financial indebtedness of the listed entity	0.00	
	including short term and long-term debt		

ANNEXURE D: FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (APPLICABLE ONLY FOR HALF-YEARLY FILINGS I.E., 2ND AND 4TH QUARTER) :- **NOT APPLICABLE FOR THIS QUARTER**

ANNEXURE E: STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (STANDALONE AND CONSOLIDATED SEPARATELY) (APPLICABLE ONLY FOR ANNUAL FILING I.E., 4TH QUARTER):- NOT APPLICABLE FOR THIS QUARTER

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

RAMESH SHAH CHAIRMAN & MANAGING DIRECTOR DIN: 00028819



Biofil Chemicals and Pharmaceuticals Limited



Registered Office: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.) CIN L24233MP1985PLC002709

Email Id:bcplcompliance@gmail.com Phone No. 0731-2426718, Website: www.biofilgroup.net

(Amount in Lakhs except EPS)

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTI					(Amount in Lakins except EF5) H ENDED 31ST DECEMBER 2024		
		Quarter Ended			Nine Month Ended		Previous Year Ended
	Particulars	3 months ended on 31/12/2024	Preceeding 3 months ended on 30/09/2024	Corresponding 3 months ended in previous year on 31/12/2023	Year to date figures for Current period ended 31/12/2024	Year to date figures for Previous period ended 31/12/2023	Previous year ended on March 31 2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operation	1419.52	241.26	503.15	2505.12	2483.26	4003.53
II	Other Income	2.30	1.62	2.79	6.85	8.40	48.97
III	Total Income (I + II)	1421.82	242.88	505.93	2511.97	2491.66	4052.50
IV	Expenses						
	(a) Cost of materials consumed	213.12	42.16	166.01	323.90	1593.76	525.743
	(b) Purchases of stock-in-trade	823.35	540.11	26.87	2106.47	816.18	3252.26
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	314.61	(385.34)	253.40	(110.81)	(132.55)	(27.25)
	(d) Employee benefits expense	21.45	18.29	14.85	53.61	47.19	67.04
	(e) Finance Cost	0.98	0.90	0.01	2.94	2.06	4.15
	(f) Depreciation and Amortisation Expense	9.87	9.87	10.73	29.62	32.20	39.94
	(g) Other expenses	16.27		22.73	58.01	73.77	
	1. Manufacturing Expenses	11.19	8.01	10.79	31.12	32.48	61.34
	2. Administrative Expenses	4.62	4.41	3.10	20.67	19.14	38.43
	3. Selling and Distribution Expenses	0.46	1.18	1.49	6.22	4.91	4.31
	Total expenses (IV)	1399.65	239.60	494.60	2463.74	2432.61	3965.97
V	Profit/ (Loss) before exceptional items and tax (III-IV)	22.16	3.27	11.33	48.23	59.05	86.53
VI	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
VII	Profit/ (Loss) before tax (V - VI)	22.16	3.27	11.33	48.23	59.05	86.53
VIII	Tax expense:						
	(1) Current tax	5.71	0.84	2.00	12.42	13.00	24.00
	(2) Deferred tax Credit/(Charge)	0.00	0.00	0.00	0.00	0.00	()
	Total Tax expenses	5.71	0.84	2.00	12.42	13.00	15.61
IX	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00	0.00	0.00	0.00	0.00
X	Profit/(Loss) for the period from continuing operation (VII-VIII)	16.46	2.43	9.33	35.81	46.05	70.92
XI	Profit/(Loss) from dis-continued operation before tax	0.00	0.00	0.00	0.00	0.00	0.00
XII	Tax expenses of discontinued operation	0.00	0.00	0.00	0.00	0.00	0.00
XIII	Profit/(Loss) from dis-continued operation after tax (XI-XII)	0.00	0.00	0.00	0.00	0.00	0.00
XIV	Share of profit (loss) of associates and joint ventures accounted for using equity method	0.00	0.00	0.00	0.00	0.00	0.00
XV	Profit/ (Loss) for the period (X+XIII)	16.46	2.43	9.33	35.81	46.05	70.92
XVI	Other Comprehensive Income	0.00	0.00	0.00	0.00	0.00	0.00
	A) (I)Items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	25.67
	(II) Income Tax relating to items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	(6.46)
	B) (i) Items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	(II) Income Tax relating to items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00

XVII	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit or Loss and other						
	Comprehensive income for the period)	16.46	2.43	9.33	35.81	46.05	90.13
XVIII	Paid-Up equity share capital (face value of Rs 10/-each)	1627.38	1627.38	1627.38	1627.38	1627.38	1627.38
XIX	Reserves (Excluding Revaluation Reserve)						(183.30)
XX	Earnings per equity shares (for continuing operation):						
	(1) Basic (Rs)	0.10	0.01	0.06	0.22	0.28	0.44
	(2) Diluted (Rs)	0.10	0.01	0.06	0.22	0.28	0.44
XXI	Earnings Per Equity Share (for discontinued operation)						
	(1) Basic (Rs)	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Diluted (Rs)	0.00	0.00	0.00	0.00	0.00	0.00
XXII	Earnings Per Equity Share (for continuing & discontinued operation)						
	(1) Basic (Rs)	0.10	0.01	0.06	0.22	0.28	0.44
	(2) Diluted (Rs)	0.10	0.01	0.06	0.22	0.28	0.44

The above unaudited financial results for the Quarter and nine month ended December 31, 2024 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in it's meeting held on February 11, 2025. The above results have been reviewed by statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, who have expressed an unmodified opinion. The Company's Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.

- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- The Company has reported segment wise information as per Indian Accounting Standard (Ind AS-108). The Operations of the Company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments
- a. Pharma Division
 - b. Chemicals Division.
- 4 The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary.
- The aforesaid un-audited financial Results will be uploaded on the Company's website www.biofilgroup.net and will also be available on the websites of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com for the benefit of shareholders and investors.

Date: 11th February, 2025

Place: Indore FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.

Ramesh Digitally signed by Ramesh Shah Date: 2025.02.11 17:16:18 +05'30'

RAMESH SHAH
CHAIRMAN & MANAGING DIRECTOR
(DIN: 00028819)





Registered Office: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.) CIN L24233MP1985PLC002709

Email Id:bcplcompliance@gmail.com Phone No. 0731-2426718, Website: www.biofilgroup.net

Segment wise Revenue, Results and Capital Employed for quarter ended and nine month ended 31st December 2024

(Amount in Lakhs)

		QUARTER ENDED			NINE MONTH ENDED Year Ended			
S.No.	Particulars	3 months ended on 31/12/2024 Unaudited	Previous 3 months ended on 30/09/2024 Unaudited	Corresponding 3 months ended in previous year on 31/12/2023 Unaudited	Year to date figures for Current period ended 31/12/2024 Unaudited	Year to date figures for Previous period ended 31/12/2023 Unaudited	Previous Year ended on 31/03/2024 Audited	
1	Segment Revenue							
	Pharma Unit	1,204.77	182.20	179.12	2,126.60	1,271.71	2,786.79	
	Chemicals Division	214.75	59.06	324.03	378.52	1,211.55	1,216.74	
	Gross Turnover	1,419.52	241.26	503.15	2,505.12	2,483.26	4,003.53	
2	Segment Results							
	Pharma Unit	-2.34	-7.02	-4.14	-7.40	-22.07	1.07	
	Chemicals Division	25.41	11.20	15.41	58.30	82.87	88.56	
	Total Segment Profit Before Tax	23.07	4.18	11.27	50.90	60.80	89.63	
	Interest Income	0.06	0.00	0.07	0.11	0.13	0.85	
	Interest Expenses	0.97	0.90	0.00	2.78	1.88	3.95	
	Other Unallocable Income net of Expenditur	e						
	Profit Before Tax	22.16	3.28	11.33	48.23	59.05	86.53	
3	Capital Employed Segment Assets (A)							
	Pharma Division	3,040.03	1,994.49	1,993.01	3,040.03	1,993.01	2,347.94	
	Chemicals Division	1,478.95	2,111.29	2,251.55	1,478.95	2,251.55	2,360.33	
	Total (A)	4,518.98	4,105.77	4,244.56	4,518.98	4,244.56	4,708.27	
	Segment Liabilities (B)							
	Pharma Division	2,483.46	1,422.05	1,658.78	2,483.46	1,658.78	1,976.69	
	Chemicals Division	179.41	868.56	806.80	179.41	806.80	911.30	
	Total (B)	2,662.88	2,290.60	2,465.58	2,662.88	2,465.58	2,887.99	
	Total Capital Employed (Segment Assets- Segment Liabilities)							
	Pharma Division	556.57	572.44	334.23	556.57	334.23	371.25	
	Chemicals Division	1,299.54	1,242.73	1,444.75	1,299.54	1,444.75	1,449.03	
	Total Capital Employed (Segment Assets- Segment Liabilities)	1,856.10	1,815.17	1,778.98	1,856.10	1,778.98	1,820.28	

Date: 11th February, 2025 FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.

Place : Indore

Ramesh
Shah
Shah
Shah
Place : Indore

RAMESH SHAH
CHAIRMAN & MANAGING DIRECTOR
(DIN: 00028819)



MAHESHWARI & GUPTA

CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To,
The Board of Directors
Biofil Chemicals and Pharmaceuticals Limited
Indore (M.P.)

We have reviewed the accompanying statement of unaudited Standalone Financial results ("the statement") of **Biofil Chemicals and Pharmaceuticals Limited** ("the company") for the quarter ended 31st December, 2024 and year to date from 01st April, 2024 to 31st December, 2024 attached herewith. The Statement has been prepared by the Company's Management pursuant to requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 as amended ("the listing regulations").

This statement, which is the responsibility of the Company's management and approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with rule 3 of Companies (Indian Accounting Standards) Rules, 2015 (as amended), in compliance with Regulation 33 issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures, A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would be



MAHESHWARI & GUPTA

CHARTERED ACCOUNTANTS

aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard (Ind AS) and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For MAHESHWARI & GUPTA

Chartered Accountants

FRN: 006179C

. SUNIL MAHESHWARI

Partner

M. No. 403346

Place: Indore Date: 11/02/2025

UDIN: 25403346BMIIED1075